Join the Hadlima group to help and get support from people like you.
Hadlima News
Updated FDA Labeling Recommendations for Biosimilar and Interchangeable Biosimilar Products
October 26, 2023 – Over the last eight years, FDA has approved more than 40 biosimilar products (biosimilars), and they have become an important treatment option for health care professionals and...
Treatment Effect of Tofacitinib, Adalimumab Compared in RA
WEDNESDAY, July 12, 2023 – For adults with rheumatoid arthritis (RA), there is a modest reduction in the mean Disease Activity Score in 28 joints using C-reactive protein (DAS28-CRP) at three months...
Monthly News Roundup - May 2023
FDA Approves Once-Daily SGLT Inhibitor Inpefa to Treat Heart Failure Over 6 million Americans suffer from heart failure, with the prevalence expected to rise to 8 million by 2030. In response, the US...
FDA Approves Abrilada (adalimumab-afzb), a Biosimilar to Humira
November 18, 2019 - Pfizer Inc. (NYSE: PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) has approved Abrilada™ (adalimumab-afzb), as a biosimilar to Humira® (a...
FDA Approves Hadlima (adalimumab-bwwd), a Biosimilar to Humira
INCHEON, Korea – July 24, 2019 – Samsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved Hadlima (adalimumab-bwwd), a biosimilar referencing Humira (ad...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Ankylosing Spondylitis, Crohn's Disease, Crohn's Disease - Maintenance, Plaque Psoriasis, Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis